Many countries around the world that appeared to have kicked COVID-19 are reporting surges, largely the result of the so-called “stealth” Omicron variant, BA.2.
Novartis aims to help manufacture more than 50 million doses of BioNTech’s Covid-19 vaccine in 2021 at the Swiss drugmaker’s Stein, Switzerland fill-and-finish facility after the European Union’s drug regulator approved the bottling plant.
Countries across the globe shut their borders to Britain on Dec. 21 due to fears about a highly infectious new coronavirus strain, causing travel chaos and raising the prospect of food shortages days before Britain is set to leave the European Union.
Switzerland-based Noema Pharma raised $59 million in a Series A financing round that will support the development of four clinical-stage assets the company licensed from Roche for the treatment of orphan neurological diseases with severe unmet needs.
First indications of the effectiveness of a potential vaccine against coronavirus may be available in the autumn, the head of the GAVI vaccine alliance told a Swiss newspaper, forecasting a long road from there to broad availability.
Researchers at Switzerland-based Empa, ETH Zurich and Zurich University Hospital developed a sensor that has the potential to identify SARS-CoV-2, the novel coronavirus that causes COVID-19, in the air.
Pfizer announced plans to buy Therachon, a rare disease biotech company based in Basel, Switzerland.
Switzerland will introduce a monitoring system to assuage concerns about the potential health impact of fifth-generation (5G) mobile frequency emissions and smooth the cutting-edge technology’s rollout, the government said.
Novartis will cut 2,550 jobs in Switzerland and Britain over four years as the Swiss drugmaker strives to boost profits and focus on new medicines.
China has overtaken the United States in healthy life expectancy at birth for the first time, according to World Health Organization data.